Atlantic Healthcare is an international specialty pharmaceutical company
focussed on diseases of the gastrointestinal tract and Inflammatory
Bowel Disease (IBD). The Company's lead product is alicaforsen enema, in
Phase 3 development for pouchitis, and in preparation for Phase 3
clinical development for Ulcerative Colitis. Alicaforsen is also
generating ea...

The Crohn's & Colitis Foundation (the Foundation) is the largest
non-profit, voluntary, health organization dedicated to finding cures
for inflammatory bowel diseases (IBD). The Foundationâs mission is to
cure Crohn's disease and ulcerative colitis, and to improve the quality
of life of children and adults who suffer from these diseases. The
Foundatio...

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced
clinical stage drug development Company with a platform technology that
is designed to address multi-billion dollar markets in the treatment of
cancer, inflammatory disease and sexual dysfunction. The Company's lead
drug candidate, Piclidenoson, is scheduled to enter Phase III trials in
2...

Atlantic Healthcare is an international specialty pharmaceutical company
focussed on diseases of the gastrointestinal tract and Inflammatory
Bowel Disease (IBD). The Company's lead product is alicaforsen enema, in
Phase 3 development for pouchitis, and in preparation for Phase 3
clinical development for Ulcerative Colitis. Alicaforsen is also
generating ea...

Akaal Pharma Pty Ltd (Akaal Pharma) is a clinical-stage drug discovery
and development company focused on the development of novel small
molecule drugs for the treatment of inflammatory and autoimmune diseases
including psoriasis, atopic dermatitis, multiple sclerosis, ulcerative
colitis, and rheumatoid arthritis. Akaal Pharma has created a robust
pipeline...

Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company
focused on the development and manufacture of drugs to treat and prevent
a variety of diseases and conditions, including vascular diseases
related to cancer and cancer treatments. Defibrotide, the Company's lead
product candidate, is an investigational drug that has been granted
Orphan ...

SAFE-BioPharma Association (www.safe-biopharma.org)
is the non-profit association that created and manages the
SAFE-BioPharmaÂ® digital identity and signature standard for the
pharmaceutical and healthcare industries.

The Crohn's & Colitis Foundation of America is the largest non-profit, volunteer-driven organization dedicated to finding a cure for Crohn's disease and ulcerative colitis, and it ranks third among leading health non-profits in the percentage of expense devoted to research toward a cure, with approximately 79 cents of every dollar the Foundation spends going to mission-critical programs. The organ...

Orphan Europe was started with the objective of providing orphan drugs to patients afflicted by rare disorders.Over the years an information network has been established to increase the awareness about rare disorders among healthcare professionals. The company has committed itself to provide support necessary to those working in this field. This is achieved through an extensive collaboration with ...

Synageva BioPharma Corp. is dedicated to discovering, developing and
commercializing therapies for patients with rare conditions and unmet
medical need.Â The Company has developed a pipeline of novel therapeutics
for under-served populations and has assembled a team with a proven
record of bringing orphan therapies to patients. Additionally, Synageva
is ...

Array BioPharma is a drug discovery company inventing new small molecule drugs through the integration of chemistry, biology and informatics. Our experienced scientists use the Array Discovery Platform, our integrated set of drug discovery technologies, to invent novel small molecule drugs in collaboration with leading pharmaceutical and biotechnology companies and to build our own pipeline of pro...

AOP Orphan is a multinational company with headquarters in Vienna,
Austria, focusing on clinical research, development and distribution of
medicines for rare and complex diseases. The company also provides
individualized and customized services to meet and accommodate the needs
of physicians and patients across Europe, the Middle East & Asia.
Currently AOP...

Incara Pharmaceuticals Corporation focuses on the protection and regeneration of tissue damaged by injury and disease. The company currently has programs in three areas: liver cell therapy and progenitor cell therapy as a treatment for liver failure; small molecule catalytic antioxidants as treatment for stroke and tissue damage; and deligioparin (formerly named OP2000), an ultra-low molecular wei...

Protein Therapeutics, Inc. was founded in 1997 to discover and develop new therapies for chronic diseases.The initial focus of the company is to develop an oral formulation of human immunoglobulin (IgPO) to treat adult and juvenile rheumatoid arthritis, crippling diseases that affect more than 2.1 million people in the United States.Upon successful completion of this goal, Protein Therapeutics wil...

Exmoor pharma concept is a small friendly and innovate consultancy,specialising in biopharma and secondary pharma and helping our clients to develop their facilities and manufacturing strategies.This site describes our team,our project experience,our approuch and the services we offer.

Alizyme is a speciality biopharmaceutical development company, based in Cambridge, UK. We are focused on developing products for the treatment and management of gastrointestinal disorders involving inflammation, such as ulcerative colitis, and motility, such as irritable bowel syndrome, of obesity and related diseases, such as diabetes, and of the gastrointestinal side effects of cancer therapy, s...

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies. For more information on the Company, visit http://www.genesis-biopharma.com.

Cureveda LLC was co-founded in 2010 by Johns Hopkins Bloomberg School of
Public Health faculty members Shyam Biswal and Rajesh Thimmulappa
together with Christy Wyskiel. The company is focused on the discovery,
development and commercialization of drugs for the treatment of
inflammatory, autoimmune and neurogenerative diseases. Cureveda is
developing Nrf2 ...

As part of the National Health Information Sharing and Analysis Center
(NH-ISAC), SAFE-BioPharma Association, LLC [www.safe-biopharma.org]
provides global, high-assurance identity trust for cyber-transactions in
the biopharmaceutical and healthcare industries.

Ansun BioPharma is a clinical stage biopharmaceutical company focused on
the development of unique host-directed anti-viral therapies for
respiratory viruses. Ansun BioPharma has two products in late stage
clinical development. FluDaseTM is a first-in-class
broad-spectrum investigational therapeutic agent to treat all forms of
influenza, including pandemic...

Santhera Pharmaceuticals is a Swiss biopharmaceutical company focusing on the discovery, development and marketing of small molecule pharmaceutical products for the treatment of neuromuscular diseases. Santhera’s vision is to become the leading specialty pharmaceuticals company offering therapies for a number of indications in this area of high unmet medical need which includes many orphan indic...

TenX Biopharma, Inc., is a biopharmaceutical company focused on late stage development and commercialization of novel monoclonal antibody-based cancer therapies. TenX Biopharma acquired global rights to zanolimumab in February, 2010 from Genmab (CO:GEN) in conjunction with a financing led by Zoticon Bioventures. For more information visit www.tenxbiopharma.com.

Taking great care of our patients.Looking back, it’s hard to believe what started as a two-physician pediatric subspecialty practice in Broward County, Florida became the modern Pediatrix Medical Group. But this ordinary business arrangement initiated some extraordinary approaches to clinical practice management and patient care. We linked pediatric and obstetric sub-specialists to one another s...